Below are current clinical trials.6 studies in Hypoplastic left heart syndrome
(open studies only).
Filter this list of studies by location, status and more.
This is a Phase I study to determine the safety and feasibility of injections of autologous umbilical cord blood (UCB) cells into the right ventricle of Hypoplastic Left Heart Syndrome (HLHS) children undergoing a scheduled Glenn surgical procedure. The investigators are doing this research study to find out if autologous stem cells from the individual's own umbilical cord blood can be used to strengthen the muscle of the right side of their heart. This will help determine the safety and feasibility of using cell-based regenerative therapy as an additional treatment for the management of HLHS.
The primary objective of the study is to utilize comprehensive, family-centered genomic screening strategies - chromosomal microarray (CMA) and whole genome sequencing (WGS) - to discover the genetic bases for Hypoplastic Left Heart Syndrome (HLHS), a severe type of congenital heart disease characterized by underdevelopment of left heart structures.
The purpoose of this study is to improve our ability to non-invasively assess the function of the right side of your heart when it is supplying blood to your body.
The purpose of this study is to validate novel echocardiographic parameters and algorithms to quantitatively evaluate right ventricular function in patients with Hypoplastic Left Heart Syndrome (HLHS) by applying these methods to previously acquired echocardiographic examinations.
Cell-based cardiac regeneration has been the focus of acquired, adult heart disease for many years. However, congenital heart disease with severe structural abnormalities may also be reasonable targets for cell-based therapies. Interestingly, the pediatric heart is naturally growing and may be the most amendable to regenerative strategies. Therefore, identifying autologous cells (cells from the patient's own body) would be important to initiate these studies.
This study aims to validate the use of umbilical cord blood as a source of autologous cells for the purpose of cardiac repair of congenital heart disease. Cells will be isolated from the cord blood to help us determine the feasibility of collection, processing, and storage of these samples at the time of birth of infants with prenatal diagnosis of hypoplastic left heart syndrome. This study may be useful for the development of pre-clinical and clinical studies aimed at the long-term goal of repairing damaged heart muscle.
Hypoplastic left heart syndrome (HLHS) is a severe form of congenital heart disease that consists of multiple obstructions to flow through the left heart and aorta, as well as hypoplasia of the left ventricle. Most patients require a three-stage surgical protocol starting within days of birth. Stage I of this process is the Norwood reconstruction (within the first few days of life), Stage II (usually required within 3-8 months) involves creation of a direct connection between the patient's superior vena cava and the pulmonary arterial confluence (bidirectional Glenn anastomosis), and the last stage is creation of a Fontan circulation (typically within the first 2-4 years). This "single ventricle" approach requires the right ventricle to perform as the only circulatory pump for the entire body.
Our long-term goal is to develop regenerative strategies to strengthen and augment the right ventricular muscle of the single-ventricle heart following surgical palliation in HLHS patients. To determine the safety and feasibility of a cell-based therapeutic intervention at the Stage II surgery, we aim to document the natural history of post-surgical care in HLHS patients having undergone standard of care with protocol specific follow-up over the course of a 6-month period.
This prospective study will document the natural history in patients with HLHS after planned Stage II surgical palliation with a focus on cardiovascular parameters within 6 months following surgery in 10-20 patients.
Aug. 12, 2017
- Marshall A. Hypoplastic left heart syndrome. http://www.uptodate.com/home. Accessed Sept. 16, 2015.
- Facts about hypoplastic left heart syndrome. Centers for Disease Control and Prevention. http://www.cdc.gov/ncbddd/heartdefects/HLHS.html. Accessed Sept. 16, 2015.
- Single ventricle defects. American Heart Association. http://www.heart.org/HEARTORG/Conditions/CongenitalHeartDefects/AboutCongenitalHeartDefects/Single-Ventricle-Defects_UCM_307037_Article.jsp. Accessed Sept. 16, 2015.
- Bonow RO, et al. Congenital heart disease. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 10th ed. Philadelphia, Pa.: Saunders Elsevier; 2015. http://www.clinicalkey.com. Accessed Sept. 16, 2015.
- Waltzman M. Initial evaluation of shock in children. http://www.uptodate.com/home. Accessed Sept. 16, 2015.
- What are congenital heart defects? National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/chd. Accessed Sept. 16, 2015.
- Said SM, et al. Longer-term issues for young adults with hypoplastic left heart syndrome: Contraception, pregnancy, transition, transfer, counselling, and re-operation. Cardiology in the Young. 2011;21:93.
- Goldberg CS, et al. Neurodevelopment and quality of life for children with hypoplastic left heart syndrome: Current knowns and unknowns. Cardiology in the Young. 2011;21:88.
- Hypoplastic left heart syndrome. Merck Manual Professional Version. http://www.merckmanuals.com/professional/pediatrics/congenital-cardiovascular-anomalies/hypoplastic-left-heart-syndrome. Accessed Sept. 16, 2015.
- Riggin ER. Allscripts EPSi. Mayo Clinic, Rochester, Minn. Aug. 4, 2015.
- Finding support. Centers for Disease Control and Prevention. http://www.cdc.gov/ncbddd/birthdefects/families-support.html. Accessed Sept. 22, 2015.
- Qureshi MY (expert opinion). Mayo Clinic, Rochester, Minn. Oct. 7, 2015.
Hypoplastic left heart syndrome